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ABSTRACT 
Dysregulated cellular metabolism is regarded as one of the hallmarks of cancer with some tumours 
utilising the glutamine metabolism pathway for their sustained proliferation and survival. Glutamate 
dehydrogenase (GLUD1) is a key enzyme in glutaminolysis converting glutamate to α-Ketoglutarate 
for entry into the TCA cycle.  
Breast cancer (BC) comprises a heterogeneous group of tumours in terms of molecular biology and 
clinical behaviour, and we have previously shown that altered glutamine metabolism varies substan-
tially among the different molecular subtypes.  
We hypothesise that the prognostic value of GLUD1 expression will differ between the BC molecular 
subtypes and may act as a potential therapeutic target for BC tumours. 
Methods: GLUD1 was assessed at the DNA, mRNA (n=1,980) and protein (n=1,300) levels in large 
and well-characterised cohorts and correlated with clinicopathological parameters, molecular sub-
types, patient outcome and treatments.  
Results: There was a correlation between GLUD1 mRNA and GLUD1 protein expression which were 
highly expressed in low grade Luminal/ER+ BC (p<0.01). GLUD1 mRNA and protein was associated 
with good patient outcome but not in any specific molecular subtypes. However, high GLUD1 protein 
expression was associated with a better outcome in triple negative (TN) patients treated with chemo-
therapy (p=0.03). 
High GLUD1 mRNA was associated with the glutamine transporter, SLC1A5, and leucine transporter, 
SLC7A8 as well as mTOR (p<0.0001).  
Conclusion: We provide comprehensive data indicating GLUD1 plays an important role in Luminal/
ER+ BC. GLUD1 expression predicts a better patient outcome and we show that it has the potential 
for predicting response to chemotherapy in TNBC patients. 
INTRODUCTION 
Dysregulated tumour metabolism is an important step in oncogenesis and is acknowledged as one of 
the revised hallmarks of cancer, whereby cancer cells are able to modify and re-programme their me-
tabolism to most effectively provide the energy required for proliferation and survival [1].  
One of the most well described metabolic changes in tumour cells is the Warburg effect where glycol-
ysis is utilised to support the increased energy requirement for the rapid growth of tumour cells, even 
in the presence of oxygen [2]. Besides glycolysis, glutaminolysis is also proving to be an essential 
metabolic pathway where the amino acid glutamine (Gln) is used to sustain proliferation and survival 
[3]. Indeed, many tumour cells undergo metabolic re-programming which makes them highly depend-
able upon this amino acid, and glutamine deprivation results in growth arrest and cell death [4]. 
There is abundant evidence surrounding the regulation of dysregulated tumour metabolism by onco-
genes and/or tumour-suppressor genes such as c-Myc and p53, which are able to modulate the expres-
sion and activity of key transporters and enzymes involved in glutaminolysis [5-7]. 
BC heterogeneity is well documented and dysregulated metabolism during tumourigenesis can vary 
substantially among the different molecular subtypes of BC. Differences in metabolic profiles have 
been shown to discriminate between oestrogen receptor positive (ER+) and triple negative breast can-
cers (TNBC) [8], whereby TNBCs have an increased expression of metabolic enzymes involved in 
glutaminolysis and ER+ BCs which have the lowest level of these enzymes [9, 10].  
HER2 positive tumours have the highest levels of Gln metabolism with increased expression of Glut-
aminase (GLS) and glutamate dehydrogenase (GLUD) [10]. This is in concordance with higher levels 
of glutamate and lower levels of Gln in TNBC and HER2+ tumours compared with ER+ tumours 
suggesting an increase in Gln consumption and glutaminolysis in these tumours [8, 11]. 
Oncometabolism is rapidly becoming an attractive field for therapeutic intervention and the differ-
ences observed in metabolic signatures between ER- and ER+ tumours may further guide therapy and 
predict disease outcome as well as allowing for the emergence of novel targets for therapeutic ap-
proaches to improve efficacy and reduce resistance. 
We have previously reported the importance of the glutamine-proline regulatory axis in the highly 
proliferative luminal subgroup of BC and its regulation by MYC [12]. GLUD is a key enzyme in glut-
aminolysis converting glutamate to α-Ketoglutarate (α-KG) for entry into the TCA cycle, reducing 
NAD(P)+ to NAD(P)H in the process.  GLUD is activated by the direct binding of the essential amino 
acid leucine which stimulates the deamination of glutamate and hence the production of α-KG.  In 
humans two different isoenzymes of GLUD exist, GLUD1 and GLUD2, both of which are upregulat-
ed in human cancers enabling the cancer cell to utilise this pathway for growth and proliferation [13]. 
Studies have shown that in the cancer cell GLUD1 is not only essential for sustaining the TCA cycle 
for rapid proliferation and growth, but also has a role in the activation of mTORC1 [14] and as a regu-
lator of redox homeostasis, whereby the inhibition of GLUD1 results in imbalanced redox ho-
meostasis and a reduction in cancer cell proliferation and growth [15]. 
In this study, we aimed to determine the role of GLUD1 in BC by assessing gene copy number, 
mRNA and protein expression in large well characterised annotated cohorts of BC to determine its 
biological and clinical relevance within the different molecular subtypes, hypothesising a potential 
role within the higher proliferating, more aggressive forms of BC. 
MATERIALS AND METHODS  
GLUD1 gene expression 
GLUD1 gene expression was evaluated in a cohort of 1,980 breast cancer samples using the Molecu-
lar Taxonomy of Breast Cancer International Consortium (METABRIC) cohort [16]. The METABRIC 
study provides data on genomic and transcriptomic profiling of breast cancer using the Affymetrix 
SNP 6.0 and Illumina HT-12 v3 platforms respectively.  In addition, TP53 mutational profiling was 
performed.  Detailed description of the experimental assays and analytical methods used were de-
scribed previously [17]. In this cohort, patients with ER+ and/or lymph node negative tumours did not 
receive adjuvant chemotherapy, whilst those with ER- and/or lymph node positive tumours received 
adjuvant chemotherapy. Dichotomisation of GLUD1 mRNA expression was performed using X-tile 
(Version 3.6.1, Yale University, USA) based on prediction of breast cancer specific survival (BCSS) 
[18]. The BCSS is defined as the time (in months) from the date of primary surgery to the date of BC-
related death. The relationship between gene copy number aberrations, both gains and losses, of 
GLUD1 and MYC and p53 mutations with GLUD1 mRNA expression and patient outcome were also 
investigated.                                       
To validate the data on the GLUD1 mRNA expression, bc-GenExMiner v4.0 (Breast Cancer Gene-
Expression Miner v4.0) online dataset (http://bcgenex.centregauducheau.fr) was used as an external 
validation dataset [19]. 
GLUD1 protein expression 
Immunohistochemistry was conducted using a large cohort of patients comprising a well-charac-
terised consecutive series of early stage (TNM Stage I-III excluding T3 and T4 tumours) sporadic 
primary operable invasive BC. Patients (age ≤70 years) were enrolled into the Nottingham Tenovus 
Primary Breast Carcinoma Series, presented at Nottingham City Hospital between 1989 and 1998 
(n=1,300) and managed in accordance to a uniform protocol. Patients’ clinical history, tumour charac-
teristics, information on therapy and outcomes are prospectively maintained. Outcome data was col-
lected on a prospective basis and included development and time to distant metastasis (DM) and 
BCSS. DM free survival (DMFS) is defined as the time (in months) from the date of primary surgery 
to the appearance of DM.  
The clinicopathological parameters for Nottingham and METABRIC series of patients are sum-
marised in Supplementary Table 1.  
GLUD1 Antibody Validation 
GLUD1 primary antibody specificity (Rabbit monoclonal, Ab168352, Abcam Plc, Cambridge UK) 
was determined using western blotting with MCF7 and MDA-MB-231 human BC cell lines (obtained 
from the American Type Culture Collection; Rockville, MD, USA). GLUD1 primary antibody was 
used at a 1:250 dilution and IRDye 800CW Donkey anti-Rabbit fluorescent secondary antibody (926-
32213, LI-COR Biosciences) was used at a 1:15000 dilution. Mouse monoclonal anti-β-actin primary 
antibody (1:5000, A5441, Sigma-Aldrich) with IRDye 680RD Donkey anti-Mouse fluorescent sec-
ondary antibody (1;15000, 926-68072, LI-COR Biosciences) was used as a control. Samples were 
loaded at 10µg alongside the protein ladder (26619, PageRuler Plus Prestained Protein Ladder, Ther-
mo Scientific) to determine the correct molecular weight. Odyssey Fc with Image Studio 4.0 was used 
to visualise protein bands (LI-COR Biosciences) which showed a single specific band at the predicted 
molecular weight of 62 KDa (Figure 1A). 
Tissue arrays and Immunohistochemistry 
Tissue microarrays (TMAs) were constructed as previously described [20]. Immunohistochemical 
staining for GLUD1 was performed on 4 µm thick sections using the Novolink polymer detection sys-
tem (Leica Biosystems, RE7150-K), as per manufacturer’s instructions. Heat mediated antigen re-
trieval was carried out using citrate buffer pH 6.0. GLUD1 primary antibody was used at a 1:100 dilu-
tion for 30 minutes at room temperature. Negative (omission of the primary antibody) and positive 
controls were included according to manufacturer’s data sheet. 
Assessment of GLUD1 Protein Expression 
Stained TMA sections were assessed using high resolution digital images (NanoZoomer; Hamamatsu 
Photonics, Welwyn Garden City, UK) at x20 magnification. Assessment of staining for GLUD1 was 
based on a semi-quantitative assessment of immunoreactivity  using a modified histochemical score 
(H-score) which includes an assessment of both the intensity of staining and the percentage of stained 
cells [21]. For the intensity, a score index of 0, 1, 2 and 3 corresponding to negative, weak, moderate 
and strong staining was used and the percentage for each was estimated subjectively. A final score of 
0 to 300 is the product of both the intensity and the percentage.  
Scoring was carried out by KC and for inter-observer concordance, 10% of the cores were second 
scored by a pathologist (MA) blinded to previous scores, clinicopatholigcal variables and survival 
data.  
Dichotomisation of GLUD1 protein expression was determined based on breast cancer specific sur-
vival (BCSS) using X-tile software [18].  
Immunohistochemical staining and dichotomisation of the other biomarkers included in this study 
were as per previous publications [5]. ER and PgR positivity was defined as ≥1% staining. Im-
munoreactivity of HER2 was determined using standard HercepTest guidelines (Dako). Chromogenic 
in situ Hybridisation (CISH) was used to quantify HER2 gene amplification in borderline cases using 
the HER2 FISH pharmDx™ plus HER2 CISH pharmDx™ kit (Dako) and was assessed according to 
the American Society of Clinical Oncology guidelines. BC molecular subtypes were defined based on 
the immunohistochemical profile as: Luminal A: ER+/HER2- Low Proliferation (Ki67<10%). Lumi-
nal B: ER+/HER2- High Proliferation (Ki67≥10%). HER2-positive class: HER2+ regardless of ER 
status. Triple Negative (TN): ER-, PgR- and HER2-. Basal phenotype was defined as those tumours 
expressing cytokeratin (Ck) 5/6, and/or Ck14 and/or Ck17. 
Statistical analysis 
Statistical analysis was performed using SPSS 21.0 statistical software (SPSS Inc., Chicago, IL, 
USA). Univariate and multivariate analyses were performed by chi-squared test, Log rank and Cox 
regression analysis, respectively. One way ANOVA (Tukey) and Spearman’s Correlation coefficient 
were used for continuous data. Survival curves were analysed by the method of Kaplan-Meier (Ka-
plan and Meier, 1958). A p-value <0.05 was considered significant. This study complied with report-
ing recommendations for tumour marker prognostic studies (REMARK) criteria [22]. 
Ethics 
This study was approved by the Nottingham Research Ethics Committee 2 under the title ‘Develop-
ment of a molecular genetic classification of breast cancer’. 
RESULTS 
GLUD1 in breast cancer 
A total of 26/1,980 (1.3%) of cases showed a copy number gain of GLUD1 and 58/1,980 (2.9%) 
showed a copy number loss. The distribution of GLUD1 mRNA expression in the METABRIC cohort 
showed high expression (Log2 intensity >10.0 units in 909/1,980 (46%)). Loss of GLUD1 was corre-
lated with lower GLUD1 mRNA expression and gain of GLUD1 was associated with higher GLUD1 
mRNA expression (both p<0.001, Figure 2A). 
GLUD1 protein expression was observed in the cytoplasm of breast tumour cells ranging from absent 
to high (Figure 1B-1D), with high protein expression (>215 H-score) being observed in 367/1,300 
(28%) of tumours. There was a significant correlation between GLUD1 mRNA expression and 
GLUD1 protein expression (correlation coefficient=0.161, p=0.021). 
GLUD1 is associated with clinicopathological parameters of good prognosis 
Higher GLUD1 mRNA expression was significantly associated with lower tumour grade (Figure 3A, 
Table 2, p<0.001) and lymph node stage (Figure 3B, Table 2, p<0.001). The association between 
GLUD1 mRNA and tumour grade, but not nodal stage, was confirmed using the Breast Cancer Gene-
Expression Miner v4.0 (Supplementary Figure 1A). There was also a significant association between 
high GLUD1 mRNA and lobular and special type tumours (p<0.001, Figure 3J and Table 2). A similar 
association was observed between high GLUD1 protein expression and lower tumour grade (p=0.047, 
Table 2).  
High expression of GLUD1 mRNA and GLUD1 protein were significantly associated with ER+, and 
PgR+ tumours (all p<0.001; Table 2 and Figure 3C-D). Additionally, high GLUD1 mRNA, but not 
GLUD1 protein, expression was significantly expressed in HER2 negative tumours (p<0.001; Table 2 
and Figure 3E). High GLUD1 mRNA and GLUD1 protein was associated with non-TN tumours 
(p<0.001; Table 2 and Figure 3F).  
In addition, loss of GLUD1 copy number was associated with high grade tumours (p=0.001), ER- 
(p=0.008), HER2- (p=0.012) and TN (p<0.001) tumours (Table 1). 
GLUD1 is differentially expressed within the molecular subtypes of BC 
When comparing the levels of GLUD1 mRNA expression in the intrinsic (PAM50) molecular sub-
types, high expression was observed in Luminal A and B classes (Figure 3G, p<0.001). Association of 
GLUD1 mRNA with these classes was confirmed using the Breast Cancer Gene-Expression Miner 
v4.0 (Supplementary Figure 1F). Similarly within the METABRIC Integrative Clusters, high GLUD1 
mRNA expression was associated with clusters 2 (Luminal A and Luminal B tumours) and 7 (Luminal 
A tumours) (Figure 3H, p<0.001), and low levels of GLUD1 mRNA expression was observed in clus-
ter 10 (TN tumours). In the SCMGENE subtypes there was a higher expression of GLUD1 mRNA in 
ER+/HER2- tumours compared with HER2+ and ER-/HER2- tumours (p<0.001; Figure 3I). ER+/
HER2- Low Proliferation tumours had a significantly higher expression of GLUD1 mRNA than ER+/
HER2- High Proliferation tumours (p=0.02). 
Similarly, expression of GLUD1 protein in BC subtypes showed a significantly higher expression in 
ER+/HER2- tumours compared with the other subtypes (p<0.001, Table 2).  
Both Luminal B and Basal subtypes showed a greater copy number loss of GLUD1 (p<0.001) with a 
similar trend for GLUD1 copy number gain (Table 1).  
GLUD1 showed significant molecular association with other significant biomarkers 
We investigated correlation of GLUD1 mRNA expression with associated glutaminolytic genes using 
the METABRIC dataset which are summarised in Table 4. The genes were selected based on previous 
publications, being either regulatory genes or others that share or support the biological function of 
GLUD1. There was a positive correlation between GLUD1 with several amino acid transporters in-
cluding SLC7A5 (p<0.001) and genes involved in the glutamine-proline regulatory axis including 
ALDH18A1 (p<0.001). There was an inverse relationship between GLUD1 and MYC, and the MYC 
regulated gene NDRG2.  At the protein level, high GLUD1 was associated with low c-MYC expres-
sion (p<0.001), ALDH18A1 (p=0.007) and SLC7A5 (p=0.025) (Table 5) but not any other amino acid 
transporters or enzymes involved in glutaminolysis. 
High GLUD1 protein expression was significantly expressed in breast tumours that were negative for, 
PI3K (p<0.001) and the cell cycle regulator Cyclin E (p=0.006, Table 3). High expression of GLUD1 
was positively associated with high levels of Bcl-2 (p=0.022) and pAKTs437 (p<0.001; Table 3). 
There was no association between GLUD1 and Ki67. 
When investigating the subtypes of BC, the negative relationship between MYC and GLUD1 was only 
observed in Luminal A (p=0.001) and Luminal B (p=0.015) subtypes. In ER+ tumours, high GLUD1 
mRNA expression was specifically associated with those enzymes involved with the Pro-Gln regula-
tory axis. The majority of amino acid transporters were significantly associated with GLUD1 expres-
sion in ER+ tumours and to a lesser extent TN and Basal tumours. SLC1A5, SLC38A1, SLC7A5, and 
SLC7A8 were significantly expressed with GLUD1 in all subtypes. Correlations between GLUD1 ex-
pression and mTOR were observed in the Luminal A and Basal molecular subtypes, along with VEG-
FA, whereas VEGFB was only seen in ER+/HER2- tumours (Table 4).  A similar pattern of co-expres-
sion of GLUD1 and other genes was observed using the Breast Cancer Gene-Expression Miner (Sup-
plementary Table 2) particularly in ER+ tumours with genes involved in the Pro-Gln regulatory axis. 
GLUD1 expression is associated with patient outcome and response to chemotherapy 
High GLUD1 mRNA (p<0.001) and GLUD1 protein (p=0.006) expression were both associated with 
a good BCSS (Figure 4A and 4B).  However, when investigating associations with outcome within the 
molecular subtypes, high expression of GLUD1 was only predictive of longer BCSS in Luminal A 
tumours at the mRNA level (p=0.027, data not shown). There was no association between GLUD1 
mRNA or protein and outcome in the other molecular subtypes.  
The relationship between high GLUD1 mRNA expression and good patient outcome in ER+ disease, 
but not ER- disease, was confirmed using Breast Cancer Gene-Expression Miner (Supplementary 
Figure 2). CN loss or gain of GLUD1 was associated with poor patient survival (p=0.002; p=0.044) 
(Figure 2B and 2C). 
In multivariate Cox regression analysis, GLUD1 protein, but not GLUD1 mRNA, was an independent 
predictor of BCSS in all cases (p=0.005) (Table 6).   
When considering TNBC patients treated with chemotherapy, patients with high GLUD1 protein ex-
pression had a significantly better outcome (Figure 5C, p=0.027) whilst those patients who did not 
receive chemotherapy had no survival advantage (Figure 5B, p=0.570).  
DISCUSSION 
Metabolic reprogramming in cancer including BC provides a vital role in the provision of supplemen-
tary elements including nutrients and energy which are essential for cellular growth. Some tumour 
cells are reliant on glutamine metabolism and become “addicted” to this amino acid for sustained pro-
liferation/survival. 
Studies that address the prognostic significance of the enzyme GLUD1 in BC and its potential influ-
ence on Gln metabolism remains limited.  
We therefore investigated GLUD1 at the genomic, transcriptomic and proteomic level utilising a large 
number of breast tumours in order to better understand the potential role of this enzyme in BC and its 
molecular subtypes.  
In this study, we have shown for the first time that high GLUD1 expression at the mRNA and protein 
level is associated with tumours of good prognosis; specifically tumours of lower grade and hormone 
receptor positivity (ER+/PR+).  
Kim et al., 2013, investigated the expression of glutamine metabolism-related proteins in a smaller 
study, including GLUD1, within the different molecular subtypes of breast cancer showing that high 
expression of tumoural GLUD1 protein was observed in the HER2+ and Luminal A/B subtypes com-
pared with TNBC [10]. In our study, we confirm the relationship with GLUD1 and luminal tumours 
but we found no correlation between GLUD1 expression and HER2+ tumours. 
We did observe a CN loss of GLUD1 which was significantly associated with ER-, HER2- and TN 
tumours as well as a greater CN loss being observed in Basal-like tumours. 
Several studies have been carried out looking at quantitative proteomics to generate profiles in order 
to identify functional differences between the BC molecular subtypes [23, 24]. From these studies 
noticeable differences in energy metabolism networks between the subtypes of BC were revealed, 
suggesting the use and synthesis of metabolites to support growth and survival differs within each of 
the subtypes. For example, a significant increase in energy metabolism was observed in ER/PgR 
‘Luminal-like’ tumours compared to a down regulation of this pathway in HER2+ tumours. KEGG 
and STRING analysis show higher expression of GLUD1 and glutamate-ammonia ligase/glutamine 
synthetase (GLUL) with lower expression of GLS within the ER+/PR+ tumours compared to the 
HER2+ and TNBC, however within the HER2 subtype upregulation of PYCR1 and PRODH, in-
volved in proline metabolism, were observed [24]. 
ER+/PR+ tumours were also predicted to have higher oxidative metabolism while the other subtypes 
have higher dependence on glucose and glutamine, with entire metabolic networks being associated 
with reduced glycolysis and increased oxidative phosphorylation in ER+/PR+ tumours [24]. 
Another study using computational modelling and metabolic phenotypic analysis (MPA), showed 
considerable metabolic differences between ER+ and ER- tumours, with 73% of metabolic processes 
having significantly different MPA scores. This study identified an increase in glutamine uptake to be 
typical of ER- tumours and an increase in glutamine production and secretion to be typical of ER+ 
tumours showing glutamine biosynthesis and secretion is significantly higher in ER+ whereas serine 
metabolism and glutamine uptake were significantly higher in ER- tumours [23]. These observation 
support the outcome of our study where we have shown the metabolic biosynthesis involving GLUD1 
to be associated with the Luminal subtypes of BC. 
The association of GLUD1 at the mRNA and protein level with key amino acid transporters and en-
zymes involved in glutaminolysis is not unsurprising. GLUD1 is the key enzyme in the second deam-
ination step of glutaminolysis, where it is activated by the amino acid leucine to deaminate glutamate 
to α-KG for incorporation into the TCA cycle, which is a crucial anaplerotic step in proliferating cells. 
Leucine is known to activate mammalian target of rapamycin complex 1 (mTORC1) which has many 
functions in the cancer cell including; regulation of protein translation, prevention of apoptosis and 
cancer cell proliferation [25]. 
Several studies have shown the importance of glutaminolysis in the mTOR signalling pathway which, 
when active, mTORC1 is known to have a major role in promoting cancer cell growth and prolifera-
tion.  mTORC1, one of the two multi-protein complexes, is regulated by several upstream signals in-
cluding growth factors and nutrients such as amino acids and glucose. The amino acid leucine is 
thought to be a key activator of mTORC1 by stimulating the GTP state of the RagA/B complex which 
in turn recruits mTORC1 to the lysosome where it is activated by the lysosome-associated Rheb [26, 
27].  
Glutamine has also been implicated as an important amino acid for mTORC1 signalling as it can indi-
rectly stimulate this pathway by increasing the uptake of leucine [28]. Recent findings also suggest 
leucine stimulates mTORC1 indirectly through glutaminolysis. Duran et al., 2012, demonstrated that 
glutamine, in combination with leucine, increased the GTP charge of exongenously expressed RagB, 
promoting mTORC1 activation and enhancing glutaminolysis and α-KG production, suggesting glut-
aminoloysis and α-KG production may be key events for leucine to activate Rag-mTORC1 signalling 
[14]. As it is known that leucine directly binds and regulates GLUD1, enhancing the conversion of 
glutamate into α-KG, it was proposed that mTORC1 senses the fluctuations of glutamine and leucine 
together by sensing leucine-dependent production of α-KG. However, as leucine isn’t the only activa-
tor of GLUD1, several mechanisms could be at play [29]. 
Several of the amino acid transporter molecules are involved in transporting leucine into the cell in 
exchange for glutamine, including SLC7A5 and SLC7A8. 
In this study we observed high GLUD1 expression at the mRNA and the protein level to have an in-
verse correlation with the solute carrier SLC7A5 and a positive correlation with SLC7A8 at the 
mRNA level. SLC7A5 is highly associated with TNBC and SLC7A8 with ER+ tumours, suggesting 
within Luminal/ER+ tumours, SLC7A8 has a higher affinity for leucine transport which activates 
GLUD1 for its energy metabolism. 
We also know that the Akt signalling pathway can activate mTORC1 via the TSC complex and that 
mTORC2 can activate Akt by the phosphorylation of Ser487. We have also showed at the protein lev-
el that high GLUD1 is associated with pAKTs487, suggesting the importance of this pathway within 
Luminal BC for proliferation and survival. 
In this study, we have shown that GLUD1 is highly expressed in ER+ Luminal tumours and are relat-
ed with good overall patient outcome. We have also shown high GLUD1 is associated with the trans-
porters of glutamine and leucine and mTOR, suggesting this is the metabolic pathway utilised by 
these tumours for cell survival and proliferation. 
In addition, we observed good patient outcome within TNBC patients who had high GLUD1 protein 
expression and received chemotherapy, compared with patients who did not receive chemotherapy. 
Further validation studies are required to confirm whether GLUD1 is able to predict response to 
chemotherapy within the poor prognostic TN patients. 
Table 1: Copy Number Aberrations (CNA) of GLUD1 in breast cancer and their associations with 
MYC CNA and BC molecular subtypes  
GLUD1 copy number
No Loss Gain χ2 
(p-value)
Grade
1 169 (99.4) 0 1 (0.6) 18.0 (0.001)
2 745 (96.8) 22 (2.9) 3 (0.4)
3 896 (94.1) 36 (3.8) 20 (2.1)
Lymph Node 
Stage
1 995 (96.1) 26 (2.5) 14 (1.4) 3.3 (0.507)
2 593 (95.3) 23 (3.7) 6 (1.0)
3 301 (95.3) 9 (2.8) 6 (1.9)
Estrogen 
Receptor
Negative 442 (93.2) 22 (4.6) 10 (2.1) 9.7 (0.008)
Positive 1454 (96.5) 36 (2.4) 16 (1.1)
Progesterone 
Receptor
Negative 892 (94.9) 34 (3.6) 14 (1.5) 3.5 (0.178)
Positive 1004 (96.5) 24 (2.3) 12 (1.2)
HER2
Negative 1656 (95.6) 57 (3.3) 20 (1.2) 8.9 (0.012)
Positive 240 (97.2) 1 (0.4) 6 (2.4)
Triple Negative
No 1063 (96.6) 37 (2.2) 20 (1.2) 18.8 (0.00008)
Yes 293 (91.6) 21 (6.6) 6 (1.9)
PAM50 subtype
Luminal A 703 (97.9) 10 (1.4) 5 (0.7) 42.1 (0.000001)
Luminal B 458 (93.9) 20 (4.1) 10 (2.0)
Basal 301 (91.5) 23 (7.0) 5 (1.5)
HER2 231 (96.3) 3 (1.3) 6 (2.5)
Normal 197 (99.0) 2 (1.0) 0
SCMGENE
ER+/HER2- Low 
proliferation 
361 (98.1) 4 (1.1) 3 (0.8) 15.0 (0.021)
ER+/HER2- 
High 
proliferation
352 (95.7) 12 (3.3) 4 (1.1)
ER-/HER2- 140 (92.7) 9 (6.0) 2 (1.3)
HER2+ 108 (98.2) 0 2 (1.8)
Table 2: Clinicopathological associations of GLUD1 mRNA and GLUD1 protein expression 
in breast cancer 
GLUD1
mRNA protein
Low 
n (%)
High 
n (%)
χ2 
(p-value)
Low 
n (%)
High 
n (%)
χ2 
(p-value)
Tumour size (cm)
<2.0 344 (55.3) 278 (44.7) 0.52  
(0.473)
443 (69.5) 194 (30.5) 3.85 
(0.050)
≥2.0 713 (53.6) 618 (46.4) 503 (74.4) 173 (25.6)
Grade
1 59 (34.7) 111 (65.3) 114.3 
(1.49x10-25)
140 (67.6) 67 (32.4) 6.107 
(0.047)
2 340 (44.2) 430 (55.8) 300 (39.8) 130 (30.2)
3 632 (66.4) 320 (33.6) 505 (75.0) 168 (25.0)
Histological type
Ductal 
(including 
mixed)
910 (55.7) 724 (44.3) 42.9  
(2.7x10-9) 806 (72.3) 309 (27.7)
5.74 
(0.220)
Lobular 60 (40.80 87 (59.2) 76 (69.1) 34 (30.9)
Medullary-
like
27 (84.4) 5 (15.6) 27 (87.1) 4 (12.9)
Special type 38 (33.6) 75 (66.4) 37 (64.91) 20 (35.1)
Lymph Node Stage
1 515 (49.8) 520 (50.2) 18.5 (0.0001) 585 (73.8) 208 (26.2) 4.53 
(0.104)
2 354 (56.9) 268 (43.1) 282 (68.3) 131 (31.7)
3 197 (62.3) 119 (37.7) 78 (64.9) 26 (25.0)
Estrogen Receptor
Negative 385 (81.2) 89 (18.8) 184.7 
(4.5x10-42)
275 (82.3) 59 (17.7) 23.50 
(0.000001)Positive 686 (45.6) 820 (54.4) 662 (68.5) 304 (31.5)
Progesterone Receptor
Negative 611 (65.0) 329 (35.0) 85.8  
(1.6x10-32)
390 (76.0) 123 (24.0) 6.56 
(0.010)Positive 460 (44.2) 580 (55.8) 518 (69.4) 228 (30.6)
HER2
Negative 892 (51.5) 841 (48.5) 38.4  
(5.8x10-10)
776 (71.0) 313 (29.0) 3.07 
(0.080)Positive 179 (72.5) 68 (27.5) 128 (77.6) 37 (22.4)
Triple Negative
No 801 (48.3) 859 (51.7) 141.0 
(1.6x10-32)
724 (69.2) 322 (30.8) 26.47 
(2.7x10-7)Yes 270 (54.1) 50 (15.6) 197 (86.0) 32 (14.0)
SCMGENE/
IHC 
molecular 
subtypes
ER+/HER2- 
High 
Proliferation
179 (48.6) 189 (51.4)
285 (67.4) 138 (32.6)
ER+/HER2- 
Low 
Proliferation
153 (41.6) 215 (58.4) 106.9 
(5.1x10-23) 198 (68.8) 90 (31.3) 27.7 (0.000004)
Triple 
Negative
130 (86.1) 21 (13.9) 200 (84.7) 36 (15.3)
HER2+ 81 (73.6) 29 (26.4) 128 (77.6) 37 (22.4)
Table 3: Expression of GLUD1 in breast cancer and the expression of other molecular bio-
markers 
GLUD1
Low, n (%) High, n (%) χ2 (p-value)
c-MYC
Negative 415 (48.7) 437 (51.3) 19.077 
(<0.001)Positive 111 (67.3) 54 (32.7)
BCL2
Negative 211 (55.8) 167 (44.2) 5.235 
(0.022)Positive 376 (48.6) 397 (51.4)
Cyclin E
Negative 169 (45.6) 202 (54.4) 7.695 
(0.006)Positive 54 (62.1) 33 (37.9)
Ki67
Negative 173 (50.9) 167 (49.1) 0.521 
(0.47)Positive 403 (53.2) 354 (46.8)
pAKTs437
Negative 135 (61.6) 84 (38.4) 15.381 
(<0.001)Positive 290 (46.3) 337 (53.7)
PI3K
Negative 346 (47.3) 385 (52.7) 12.555 
(<0.001)Positive 484 (50.5) 474 (49.5)
Table 4: Correlation of GLUD1 mRNA expression with other glutamine-related genes 
GLUD1 mRNA
All cases 
(n=1,980)
Luminal A 
(n=368)
Luminal B 
 (n=367)
HER2+ 
(n=110)
Basal 
(n=150)
Correlation Coefficient (p-value)
MYC -0.204 (3.9x10-20) -0.127 (0.001) -0.110 (0.015) -0.111 (0.085) 0.015 (0.785)
NDRG2 -0.072 (0.001) -0.007 (0.850) 0.002 (0.970) -0.060 (0.352) -0.040 (0.475)
GLS 0.039 (0.087) 0.151 (0.000049) 0.173 (0.000122) 0.029 (0.656) 0.117 (0.033)
ALDH4A1 0.159 (1.1x10-12) 0.078 (0.037) -0.040 (0.377) 0.120 (0.063) 0.232 (0.000022)
PRODH 0.046 (0.463) 0.131 (0.163) 0.041 (0.727) 0.212 (0.383) 0.040 (0.858)
PYCR1 -0.070 (0.002) -0.002 (0.954) -0.020 (0.662) 0.051 (0.432) -0.123 (0.026)
ALDH18A
1
0.110 (9.8x10-7) 0.201 (5.6x10-8) 0.158 (0.000458) 0.278 (0.000013) 0.091 (0.100)
GLUL 0.272 (0.000011) 0.166 (0.077) 0.402 (0.000385) -0.256 (0.290) 0.081 (0.713)
SLC1A5 0.130 (9.8x10-7) 0.255 (3.6x10-12) 0.192 (0.000019) 0.202 (0.002) 0.128 (0.020)
SLC38A1 0.334 (1.4x10-17) 0.297 (4.8x10-16) 0.183 (0.000048) 0.313 (7.7x10-7) 0.108 (0.049)
SLC38A2 0.154 (6.1x10-12) 0.207 (2.1x10-8) 0.154 (0.001) 0.082 (0.207) 0.188 (0.001)
SLC38A3 -0.029 (0.200) 0.048 (0.186) 0.154 (0.001) 0.077 (0.235) -0.117 (0.034)
SLC38A5 -0.125 (2.3x10-8) -0.073 (0.050) -0.161 (0.000349) -0.073 (0.261) -0.683 (0.135)
SLC38A7 -0.025 (0.283) 0.072 (0.053) 0.072 (0.114) 0.053 (0.415) 0.059 (0.283)
SLC38A8 -0.047 (0.035) -0.041 (0.275) -0.046 (0.314) -0.119 (0.066) -0.066 (0.232)
SLC7A11 -0.027 (0.230) -0.013 (0.721) 0.074 (0.100) 0.017 (0.798) -0.044 (0.421)
SLC7A5 -0.380 (4.4x10-69) -0.161 (0.000014) -0.237 (1.1x10-7) -0.148 (0.022) -0.112 (0.042)
SLC7A6 -0.205 (3.7x10-20) -0.127 (0.001) -0.152 (0.001) -0.52 (0.421) 0.162 (0.003)
SLC7A7 -0.363 (1.4x10-62) -0.361 (1.4x10-23) -0.316 (8.1x10-13) -0.214 (0.001) 0.009 (0.867)
SLC7A8 0.409 (1.4x10-17) 0.275 (6.0x10-14) 0.171 (0.000144) 0.245 (0.000130) 0.128 (0.020)
SLC6A19 -0.009 (0.700) -0.041 (0.273) 0.036 (0.503) 0.030 (0.643) -0.107 (0.053)
MTOR 0.053 (0.018) 0.135 (0.000293) -0.017 (0.701) 0.053 (0.413) 0.200 (0.000264)
PIK3AP1 -0.200 (2.1x10-19) -0.060 (0.106) -0.131 (0.004) -0.157 (0.015) 0.027 (0.631)
VEGFA -0.118 (1.4x10-7) 0.097 (0.010) 0.003 (0.952) -0.083 (0.202) -0.283 (1.7x10-7)
VEGFB -0.080 (0.000390) -0.199 (7.3x10-8) -0.167 (0.000204) -0.068 (0.293) -0.090 (0.103)
AKT1 0.089 (0.000075) 0.033 (0.376) 0.027 (0.555) 0.064 (0.327) -0.046 (0.403)
Table 5: Correlation of GLUD1 protein expression with other glutamine-related proteins 
ATF4 -0.070 (0.002) 0.004 (0.915) 0.060 (0.184) 0.022 (0.737) -0.068 (0.217)
BRCA1 0.086 (0.000121) 0.102 (0.006) 0.109 (0.016) 0.092 (0.137) 0.069 (0.213)
GLUD1
Low, n (%) High, n (%) χ2 (p-value)
PRODH
Negative 546 (74.5) 187 (25.5)
0.892 (0.345)
Positive 138 (71.1) 56 (28.9)
ALDH18A1
Negative 370 (76.6) 113 (23.4)
7.362 (0.007)
Positive 307 (68.7) 140 (31.1)
ALDH4A1
Negative 337 (74.9) 113 (25.1)
0.597 (0.440)
Positive 329 (72.6) 124 (27.4)
PYCR1
Negative 195 (69.9) 84 (30.1)
1.234 (0.267)
Positive 352 (73.6) 126 (26.4)
GLS
Negative 634 (72.2) 244 (27.8)
0.304 (0.581)
Positive 91 (74.6) 31 (25.4)
SLC7A11
Negative 411 (73.7) 147 (26.3)
1.060 (0.303)
Positive 122 (77.7) 35 (22.3)
SLC7A5
Negative 581 (71.9) 227 (28.1) 5.053 (0.025)
Positive 148 (80.0) 37 (20.0)
SLC3A2
Table 6: GLUD1 and patient outcome 
Negative 434 (72.0) 169 (28.0) 1.262 (0.261)
Positive 196 (75.7) 63 (24.3)
SLC1A5
Negative 342 (70.2) 145 (29.8) 1.101 (0.294)
Positive 506 (73.0) 187 (27.0)
mRNA protein
Parameter Hazard ratio  
(95% CI)
p-value
Hazard ratio  
(95% CI)
p-value
All cases
GLUD1 0.84 0.072 0.69 0.005
LN stage
1.86 3.2x10-24 1.89 2.5x10-15
Size 1.64 0.00002 1.27 0.051
Grade
1.26 0.006 2.41 6.6x10-14
ER 0.77 0.013 0.91 0.454
Supplementary Table 1: Clinicopathological parameters of the METABRIC and Nottingham primary 
breast cancer series 
METABRIC series  
n (%)
Nottingham TMA 
series 
n (%)
Menopausal status
Pre 435 (22.0) 524 (40.3)
Post 1534 (77.4) 776 (59.7)
Age
> 50 years 1426 (78.6) 830 (63.2)
≤ 50 years 424 (21.4) 483 (36.8)
Tumour size
≤ 2cm 1337 (68.2) 637 (48.5)
> 2cm 623 (31.8) 676 (51.5)
Grade
1 169 (8.9) 207 (15.8)
2 770 (40.7) 430 (32.8)
3 952 (50.3) 673 (51.4)
Tumour type
Ductal (including mixed) 1545 (83.5) 1105 (84.2)
Lobular 148 (8.0) 110 (8.4)
Medullary-like 32 (1.7) 31 (2.4)
Miscellaneous 12 (0.6) 10 (0.8)
Special type 113 (6.1) 57 (4.3)
Lymph Node Stage
1 1035 (52.5) 793 (60.5)
2 623 (31.4) 413 (31.5)
3 315 (16.0) 104 (7.9)
Follow-up Status
Alive 1070 (55.7) 683 (52.0)
Died from Breast Cancer 505 (26.3) 434 (33.1)
Died from other causes 345 (18.0) 196 (14.9)
ER
Negative 472 (23.8) 334 (25.7)
Positive 1508 (76.2) 966 (74.3)
PgR
Negative 938 (47.4) 513 (40.7)
Positive 1042 (52.6) 746 (59.3)
HER2
Negative 1734 (87.5) 1079 (86.7)
Positive 246 (12.5) 165 (13.3)
Supplementary Table 2: Correlation of GLUD1 mRNA expression in molecular subtypes with other 
genes using Breast Cancer Gene-Expression Miner  
    
All cases 
(n=5,262)
Luminal 
(n=3,765)
HER2+ 
(n=124)
Triple negative 
(n=374)
MYC 0.02 (0.149) 0.10 (<0.0001) -0.01 (0.955) -0.07 (0.1669)
GLS -0.12 (<0.0001) -0.08 (<0.0001) -0.04 (0.699) -0.08 (0.1139)
ALDH4A1 0.17 (<0.0001) 0.10 (<0.0001) 0.25 (0.0045) 0.31 (<0.0001)
PRODH -0.05 (0.0002) 0.09 (0.0014) -0.10 (0.5714) 0.32 (0.003)
PYCR1 0.21 (<0.0001) -0.03 (0.055) 0.02 (0.803) 0.25 (<0.0001)
ALDH18A1 0.16 (<0.0001) 0.19 (<0.0001) 0.33 (0.0003) 0.15 (0.0044)
GLUL 0.26 (<0.0001) 0.20 (<0.0001) 0.07 (0.421) 0.30 (<0.0001)
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Figure 1: GLUD1 Protein Expression in Breast Cancer.  
A) Antibody validation of GLUD1 shows a single specific band is observed at the correct molecular 
weight of 62kDa. Representative photomicrographs depicting: B) negative GLUD1 expression, C) 
low GLUD1 expression and D) high GLUD1 expression in BC TMA using IHC. 
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Figure 2. GLUD1 Copy Number Aberrations and relationship with A) mRNA expression B) loss vs 
BCSS, C) amplification vs BCSS 
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Figure 3: GLUD1 expression and its association with clinicopathological parameters and 
molecular subtypes: GLUD1 and A) tumour grade, B) lymph node stage, C) ER status, D), 
PR status, E) HER2 status, F) Triple Negative status, G) PAM50 subtypes, H) METABRIC 
Integrative Clusters, I) SMCGENE subtypes, J) Histological Type (IDC=Invasive ductal car-
cinoma, IDC+ILC=Invasive ductal carcinoma and invasive lobular carcinoma, IDC-
TUB=Tubular, IDC-MUC=Mucinous, IDC-MED=Medullary, ILC=Invasive lobular carin-
coma) 
I
F=62.9, p=2.9x10-37 F=13.7, p=4.0x10-13
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Figure 4. GLUD1 and Breast Cancer Specific Survival (BCSS) at 10 years: A) GLUD1 vs BCSS in 
all cases, B) GLUD1 vs BCSS in all cases. 
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Figure 5. GLUD1 protein expression and breast cancer patient outcome in Triple Negative tumours 
according to adjuvant treatment: A) protein in patients treated with chemotherapy, B) protein in pa-
tients not treated with chemotherapy. Green=high protein expression; blue=low protein expression. 
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Sup- ple- mentary Figure 1: 
GLUD1 gene expression and its association, using Breast Cancer Gene-Expression Miner 
v4.0, with: A) lymph node stage, B) tumour grade, C) ER status, D) PR status, E) HER2 sta-
tus, F) PAM50 subtypes.  
A B
C D
E
 Supplementary Figure 2. GLUD1 mRNA and breast cancer patient outcome using Breast Cancer 
Gene-Expression Miner: A) Unselected cases, B) ER+ disease, C) ER- disease.  
A B
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